Skip to main content
SpringerLink
Log in

Olmesartan label to warn of sprue-like side effects

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. see Reactions 1432 p39; 803081129

Reference

  • FDA. FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. Internet Document : [4 pages], 3 Jul 2013

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Olmesartan label to warn of sprue-like side effects. Reactions Weekly 1461, 4 (2013). https://doi.org/10.1007/s40278-013-4524-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-013-4524-5

Search

Navigation